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Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone which are used medically for several diseases. 
However, misuse is commonly observed by athletes to promote enhancement of strength, bodyweight and performance. 
AAS are frequently obtained by internet black market from clandestine drug manufacturing laboratories, without any 
quality standards, being potentially dangerous for users. The purpose of this work was the development and application of 
a fast and simple procedure for the quantitation of stanozolol by liquid chromatography coupled to quadrupole time-of-
flight-mass spectrometry (LC-QTOF-MS) in tablets packs seized in Rio Grande do Sul state, Brazil. The samples of 
stanozolol were separated considering its pharmaceutical forms. An internal standard was added to the aliquots of the 
samples, dissolved in methanol and 5 μL were injected into the analytical system. The newly developed method has been 
validated for lower limit of quantitation (LLOQ), linearity, accuracy, precision and selectivity. The lower limit of 
quantification (LLOQ) was 0.1 µg/mL. The developed method was successfully applied to 31 samples seized by the 
Secretaria da Receita Federal do Brasil (a Brazilian federal revenue service agency). According to the results, 90.3% of 
the suspected medicines (n=31) were adulterated, and 65% exhibited higher concentrations of stanozolol than those 
indicated in the label. This work successfully established a new method for quantification of stanozolol using LC-QTOF-
MS. This method aims at contributing to the identification and quantification of this anabolic androgenic steroid frequently 
seized by federal inspection agencies. 
 






Anabolic-androgenic steroids (AAS) are synthetic 
derivatives of testosterone and they are used medically for 
the treatment of hypogonadism, metabolic disorders, 
burns, anemia, bone marrow failure, chronic renal failure 
and acquired immunodeficiency syndrome (1,2). 
However, misuse is commonly observed by athletes to 
promote strength increase, bodyweight and performance 
gain (1,3). Adverse events were associated with a variety 
of different cardiovascular diseases (4-6), liver disorders 
including peliosis hepatis, hepatocellular hyperplasia and 
carcinomas (7) and a spectrum of behavioral effects 
correlated with hyperandrogenism (8). 
Legitimate pharmaceutical grade AAS are illegally 
acquired in pharmacies. In addition, black marketed AAS 
have frequently been obtained by internet from 
clandestine drug manufacturing laboratories, without any 
quality standards. In both cases, these products can be 
potentially harmful for users promoting intoxication 
(9,10).  
In Brazil, studies indicate that erectile dysfunction 
medicines, AAS and anorexigenic products are the most 
commonly counterfeit and contraband drugs (11). 
Brazilian Federal Police reported that, from 2006 to 2011, 
one third of the 3,537 AAS analyzed products were 
counterfeit products (12). Additionally, Neves et al. 
conducted the analysis of 345 AAS positive 
medicines/dietary supplements samples and observed that 
53% were substandard, spurious, falsely labelled, falsified 
or counterfeit (SSFFC) medical products (13). The 
measurements conducted by Ribeiro et al. indicated that 
20% of seized AAS samples analyzed showed adulterants 
not described in the labels. Among those, stanozolol 
samples presented the most unusual results since none of 
the capsules had the analyte presence, showing 
adulteration with other AAS compounds and sildenafil 
citrate (14).  
Stanozolol (STZ) is an alkylated C17α steroid commonly 
detected SSFFC medical product in Brazilian scenario 
(9). It is a heterocyclic steroid derived from 
dihydrotestosterone, containing chemical alterations in 
order to increase anabolic activity and decrease 
androgenic pathways, resulting in and 
anabolic/androgenic ratio of 320/30 (15,16). Because of 
its anabolic characteristics, STZ can stimulate protein and 
erythropoietin synthesis. Therefore, it promotes body fat 
loss while preserving the lean mass to achieve the 
physical shape desired (17). Despite all the beneficial 
outcomes, STZ presents side effects such as most of the 
AAS, even with their low androgenicity. Voice changes, 
alopecia, hair growth, clitoris increase, and many others 
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have been reported. STZ particularly exhibits a high 
hepatotoxic activity, since the presence of the alkyl in 
C17-alpha reduces liver metabolization. 
Stanozolol analytical measurements can be conducted by 
several techniques. This compound can be determined in 
several biological matrices such as blood, plasma, serum, 
urine, hair, nails and oral fluid for doping control purposes 
(18). Also, it can be evaluated in pharmaceutical 
formulations in order to determine its authenticity. In this 
scenario, chromatographic approaches are the most 
established methodologies (14). Gas chromatography 
coupled to mass spectrometry (MS) is widely used for 
screening, while liquid chromatography coupled to MS or 
tandem mass spectrometry (MS/MS) ensures the required 
analysis precision, specificity and sensibility with 
minimal sample pretreatment (18,19). Moreover, 
spectroscopic methods such as proton nuclear magnetic 
resonance (1H NMR), Raman and Fourier transform 
infrared spectroscopy (FT-IR) can be applied to the 
identification and quantitation of stanozolol (14,20). In 
addition, the use of high-resolution mass spectrometry 
(HRMS) methods is suggested due to the ability to 
improve mass accuracy and enhance the selectivity of the 
target compounds and/or allow for the analysis of 
untargeted compounds. 
The aim of the present study was to evaluate the quality 
of formulations containing the anabolic steroid 
stanozolol, seized by the Secretaria da Receita Federal 
do Brasil (a Brazilian federal revenue service agency). 
For this purpose, a liquid chromatography coupled to 
quadrupole time-of-flight-mass spectrometry (LC-
QTOF-MS) method was developed and validated, being 
applied to the analysis of 31 stanozolol formulations. 
 
Materials and Methods  
 
Chemical and reagents 
 
Methanolic solutions of stanozolol and 
methyltestosterone (internal standard; IS) at a 
concentration of 1.0 mg/mL were obtained from Cerilliant 
Analytical Reference Standards (Round Rock, TX, USA). 
HPLC-grade methanol, acetonitrile and formic acid were 
purchased from Merck (Darmstadt, Germany). Water was 
purified using a Milli-Q system (Millipore, Billerica, MA, 
USA). All reference standards were > 99% purity. 
 
Preparation of standard solutions 
 
Stock solutions of stanozolol and IS were prepared at 
concentrations of 200 µg/mL and 10 µg/mL respectively, 
using methanol. These solutions were stored under 
refrigeration (2-8 °C). Working solutions with 
concentrations between 0.1 and 20 µg/mL were also 
prepared in methanol by diluting stock solutions.  
 
Chromatographic conditions and data acquisition 
 
A micrOTOF-Q III (Bruker Daltonics, Bremen, 
Germany) coupled to a Shimadzu Prominence liquid 
chromatography system (Shimadzu, Kyoto, Japan) was 
used for the analyses. Mass data were obtained with the 
following optimized conditions: capillary voltage, 3000 
V; nebulizer gas, 3 bar; drying gas, 5 L/min; drying 
temperature, 150 °C; quadrupole ion energy, 4 eV; mass 
range, m/z 50 - 350 acquired with 1 Hz. The system was 
calibrated in positive mode using a solution of sodium 
formate (10 mM) and the protonated molecular ions m/z 
329.2584 (stanozolol) and m/z 303.2325 
(methyltestosterone) were detected with a mass error 
of < 5 ppm. The following chromatographic condition 
was used: a 75 × 2.0 mm i.d., 2.2 µm, Shim-pack XR-
ODS II (Shimadzu, Kyoto, Japan) column eluted with a 
gradient of 0.1% formic acid in water (A) and acetonitrile 
(B) at a 400 µL/min flow rate and 45°C as follows: 0 – 2.5 
min, 40 – 100% of B; 2.5 – 3.5 min, 100% of B; 3.5 – 3.6 
min, 100 – 40% of B; 3.6 – 5 min, 40% of B.  
 
Sample preparation and analyses 
 
Analyses were performed using stanozolol formulations 
samples seized by the Secretaria da Receita Federal do 
Brasil. Sample classification was executed in order to 
discriminate tablet from capsules, resulting in 31 packs 
(n=29 x 100 tablets; n=2 x 50 capsules). The tablets packs 
were manufactured by a Paraguayan laboratory which has 
no health license in Brazil. The capsule packs exhibited 
no manufacturing nor expiration dates, only a handwritten 
identification of the active ingredient, concentration and 
number of capsules. The means of the weights of each 
batch were determined thought the individual 
measurements of 20 tablets and capsules (with and 
without the content). For the individual weight evaluation, 
one tablet/capsule of each pack was weighted and 
compared to the means obtained. This procedure was 
carried out according to the recommendations of the 32nd 
edition of the American Pharmacopeia (USP 43) (21). 
Afterwards, a 1 mg were weighed of the tablets/capsules 
on an analytical balance (Shimadzu, AUW220D; 
0.1mg/0.01mg) was transferred to falcon tubes and 
diluted with 4 mL of methanol, followed by 
homogenization in vortex for 30 s and centrifugation for 
10 min at 3500 rpm.  For quantitative analysis IS working 
solution (100 μg/mL) was added to all samples and an 
aliquot of 5 μL was directly injected into the analytical 
system.  
 
Optimization of the Q-TOF parameters 
 
In this step, a multivariate approach strategy based on a 
central composite design was applied for the optimization 
of three parameters that are relevant in order to obtain the 
maximum analytical response of the target compound: 
capillary voltage (1320 V; 2200 V; 3500 V; 4800 V; 5680 
V), drying temperature (150 ºC; 190 ºC; 250 ºC; 310 ºC; 
350 ºC) and collision energy (1 eV; 6 eV; 13 eV; 20 eV; 
25 eV). A total of 17 experiments were evaluated using as 
response the absolute area provided by the analyte in all 
examined conditions. The software Statistica (Statsoft, 
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EUA) was used to evaluate the experimental design 




The method was validated according to international 
guidelines and recommendations for validation of 
analytical methods, by establishing parameters such as the 
lower limit of quantitation (LLOQ), linearity, accuracy, 
precision and selectivity (22-25). The study of linearity 
was performed by injecting working standard solutions of 
the analytes at six levels: 0.1, 1, 5, 10, 15 and 20 µg/mL, 
in six replicates for each concentration. Precision and 
accuracy were performed through the analysis of three 
different levels (0.2, 8 and 16 µg/mL). Six replicates on 
each of three consecutive days were acquired and the 
precision data (within and between-day) were calculated 
using one-way analysis of variance (ANOVA). 
Selectivity was evaluated in the lowest level of precision, 
adding compounds that may be present in the sample 
(ephedrine, caffeine and sibutramine). 
 
Results and Discussion 
 
Optimization of the Q-TOF parameters 
 
The response surfaces obtained with the variable’s 
capillary voltage, temperature and collision energy are 
shown in Figure 1. According to the results, the optimized 
results of capillary voltage, temperature and collision 
energy are respectively 3000 V, 150 ºC and 4 eV. These 
values represent the highest analytical signal intensity for 
stanozolol, and they were used for subsequent validation 
and analyses. The use of multivariate approaches to 
determine the optimal conditions in experimental 
procedures is a valid and effective strategy. Traditional 
univariate approaches can be comprised of several 
empirical experiments, which can make the analysis time-
consuming and more expensive.  
 
 
Figure 1.  Response surfaces (peak area) for the evaluation of 
the Q-TOF parameters: a) Capillary Voltage (V) x Temperature 
(ºC); b) Collision Energy (eV) x Capillary Voltage (V); c) 




The LLOQ value was determined by empirical method, 
which consists of analyzing a series of samples 
concentrations of the analyte, and the LLOQ obtained was 
0.1 µg/mL (Figure 2). The calibration curve was linear 
over the specified range (0.1 – 20 µg/mL). The linear 
regression equation and the respective coefficient of 
determination were y = 0.0018x + 0.1653, r2 = 0.9975. The 
analyte has presented heteroscedastic calibration curve, 
which may be explained by the wide range of 
concentration values considered in this parameter. 
Therefore, linear least squares regression methods have 
resulted in large errors in the calculation of the 
concentrations, especially at lower values. By applying 
weighted least squares linear regression, the resulting 
weighting factor was of 1/y and the linear regression 




Figure 2. Chromatogram of stanozolol and its respective internal 
standard (methyltestosterone) at LLOQ value (0.1 µg/mL). 
 
The method selectivity was performed under the specified 
test conditions and no significant level of interfering at the 
retention time of the analyte was observed, thus 
confirming the selectivity of the method. The precision 
was assessed by ANOVA and the results obtained of 
intra-day precision presented a variation of 11.4 - 17.8%. 
For inter-day precision the results were achieved in the 
range of 11.8 to 16.7%. Results on precision and accuracy 
of the validated method are shown in Table 1. 
 
Table 1. Precision and accuracy data of the developed method 
for stanozolol formulations at three quality control (QC) levels: 





The means of the weight of tablets and capsules, so as the 
individual weights of each sample and the variation are 
summarized in Table 2. It was noted that 5 samples (4 
tablets and 1 capsule) exceeded the variation limit of ± 5% 
for tablets and ± 7.5% for capsules established by the 
regulatory agencies. These variations can directly 
influence on the content of stanozolol in the product 







QC Low 92.67 
QC Medium 95.24 
QC High 92.10 
Intra-day precision (% 
CV) 
QC Low 17.79 
QC Medium 12.05 
QC High 11.04 
 
Inter-day precision (% 
CV) 
QC Low 16.68 
QC Medium 13.88 
QC High 13.69 
CV: Coefficient of variation. 
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Table 2. Quality control data for mean weight calculated by 

















16116 14 252.50 
249.55 
2.95 1.18% 
16116 15 266.81 17.26 6.92% 
16116 18 240.09 -9.46 -3.79% 
16116 19 257.92 8.37 3.35% 
16116 21 232.87 -16.68 -6.68% 
16116 23 263.59 14.04 5.63% 
16116 24 255.95 6.40 2.56% 
16116 26 250.59 1.04 0.42% 
16116 27 257.62 8.07 3.23% 
16098 1 257.32 
250.25 
7.07 2.83% 
16098 22 244.54 -5.71 -2.28% 
16097 4 250.48 255.63 -5.15 -2.01% 
16074 12 259.04 
249.92 
9.12 3.65% 
16074 13 245.62 -4.30 -1.72% 
16063 2 242.85 
254.45 
-11.60 -4.56% 
16063 7 234.15 -20.30 -7.98% 
16063 9 261.60 7.15 2.81% 
16063 10 265.55 11.10 4.36% 
16046 25 258.84 258.23 0.61 0.24% 
16045 3 258.01 
255.58 
2.43 0.95% 
16045 11 257.00 1.42 0.56% 
16045 16 257.78 2.20 0.86% 
16045 28 255.12 -0.46 -0.18% 
16043 6 266.10 256.87 9.23 3.59% 
16041 5 244.31 
250.94 
-6.63 -2.64% 
16041 20 254.53 3.59 1.43% 
16017 8 248.65 250.01 -1.36 -0.54% 
16013 17 258.70 
256.26 
2.44 0.95% 
16013 29 258.41 2.15 0.84% 
Capsules 
NM 30 378.78 393.53 -14.75 -3.75% 
NM 31 378.87 413.18 -34.31 -8.30% 
 
After the validation of the LC-QTOF-MS method, the 
concentration of the active ingredient of stanozolol in 
each tablet and capsule was calculated. The reference 
parameter of variation of the active ingredient 
concentration was the monograph of stanozolol described 
in the 32nd edition of the American Pharmacopeia (21). 
This document defines that stanozolol tablets should not 
contain less than 90.0% or more than 110.0% of the 
labeled amount. Quantitative results for each sample 
analyzed are shown in Table 3. Variation of the content 






























16116 14 10 252.50 11.72 
16116 15 10 266.81 13.85 
16116 18 10 240.09 10.56 
16116 19 10 257.92 16.95 
16116 21 10 232.87 14.79 
16116 23 10 263.59 11.64 
16116 24 10 255.95 12.38 
16116 26 10 250.59 11.71 
16116 27 10 257.62 11.01 
16098 1 10 257.32 10.65 
16098 22 10 244.54 13.04 
16097 4 10 250.48 8.06 
16074 12 10 259.04 8.14 
16074 13 10 245.62 14.34 
16063 2 10 242.85 22.49 
16063 7 10 234.15 7.70 
16063 9 10 261.60 8.12 
16063 10 10 265.55 13.99 
16046 25 10 258.84 13.28 
16045 3 10 258.01 12.98 
16045 11 10 257.00 13.56 
16045 16 10 257.78 7.54 
16045 28 10 255.12 13.57 
16043 6 10 266.10 4.27 
16041 5 10 244.31 10.33 
16041 20 10 254.53 18.16 
16017 8 10 248.65 8.33 
16013 17 10 258.70 13.48 
16013 29 10 258.41 13.25 
  Capsules   
NM 30 20 378.78 30.06 
NM 31 250 378.87 23.29 
 
According to Figure 3, only three samples are within the 
limit of variation, with results similar than the labeled 
concentration of the seized material. Also, inaccuracy of 
the informed concentration of stanozolol has been found, 
since some of the samples exhibited double or half the 
concentration indicated on the package. Moreover, it was 
noticed a significant heterogeneity of the content in 28 
seized samples of stanozolol, and only 3 samples are 
within the concentration range regulated by the American 
Pharmacopeia (USP 43) (21). 
 
 
Figure 3. Control graph of the variation of stanozolol according 
to the limits established by the 32nd edition of the American 
Pharmacopeia. The dotted lines indicated the limits in which the 
concentration should be ranging. 
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According to the results, 90.3% of the samples appear to 
be adulterated. Of this percentage, 65% exhibited higher 
concentrations than those indicated on the package. In this 
study, the presence of other non-related substances has 
not been observed. These results exhibit correlation with 
other studies conducted in Brazil. Berneira et al. observed 
25% of counterfeit and 62.5% of adulterated formulations 
of several AAS including stanozolol (26). Ribeiro et al. 
observed three main types of adulteration of AAS: 
absence of the active ingredient, presence of other 
compounds and concentrations below those indicated. 
Stanozolol injectable solutions presented contents below 
the half of the declared on the label. Moreover, the 
capsules have shown no presence of stanozolol and the 
existence of other compounds (14). Neves et al. has 
shown that 53% of the AAS were counterfeit including 
stanozolol samples that did not present the active 
ingredient and exhibited lower or higher amount than the 
indicated (13). The main difference between this study 
and other data already published consisted of the 
adulterated samples evaluated exhibited much higher 
concentrations than those declared on the label. This 
discrepancy can be correlated with the potential increase 
of the AAS side effects already described in the literature. 
In addition, this fact can contribute in intoxication and 
overdosage processes in athletes, bodybuilders and gym 
attenders, considering the multiple cycles and drugs used 




This work successfully established a new LC-QTOF-MS 
method for stanozolol analysis. This method aimed at 
contributing to the identification and quantitation of the 
anabolic/androgenic steroid stanozolol frequently seized 
by federal inspection agencies. Quality control analyses 
were performed in 31 samples seized by the Secretariat of 
the Federal Revenue of Brazil by the evaluation of the 
means and individual weights of tablets and capsules and 
the content measurement. It was shown that 16.13% of 
samples reproved the quality control for weight and 
90.3% were adulterated. Considering only the adulterated 
samples, 65% have shown a higher concentration than the 
one indicated on the label. This study presents concerning 
data about the quality of AAS acquired in black markets 
(e.g. academies and/or internet) which can be responsible 
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